Abstract
We have previously shown that intraperitoneal vaccination with the recombinant N terminus of Als1p (rAls1p-N) modestly improves survival during murine disseminated candidiasis. We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Candida albicans / genetics
-
Candida albicans / immunology*
-
Candidiasis / immunology*
-
Candidiasis / mortality
-
Candidiasis / prevention & control*
-
Fungal Proteins / administration & dosage
-
Fungal Proteins / genetics
-
Fungal Proteins / immunology*
-
Fungal Vaccines / administration & dosage
-
Fungal Vaccines / genetics
-
Fungal Vaccines / immunology*
-
Immunologic Deficiency Syndromes / immunology
-
Mice
-
Mice, Inbred BALB C
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / genetics
-
Peptide Fragments / immunology*
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology
Substances
-
ALS1 protein, Candida albicans
-
Fungal Proteins
-
Fungal Vaccines
-
Peptide Fragments
-
Vaccines, Synthetic